Stay updated on Resmetirom in NASH and Fibrosis Clinical Trial

Sign up to get notified when there's something new on the Resmetirom in NASH and Fibrosis Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Resmetirom in NASH and Fibrosis Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    8 days ago
    Change Detected
    Summary
    The page now includes related topics such as Non-alcoholic fatty liver disease and MedlinePlus Genetics, plus a new citation for a secondary analysis of MAESTRO-NASH (Noureddin et al., 2025). To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.2%
    Check dated 2025-10-31T11:46:00.000Z thumbnail image
  3. Check
    15 days ago
    Change Detected
    Summary
    Removed the MeSH term 'Non-alcoholic fatty liver disease' and the related topic 'MedlinePlus Genetics' from the related terms on the study record. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2025-10-24T07:25:54.000Z thumbnail image
  4. Check
    22 days ago
    Change Detected
    Summary
    Removed a MedlinePlus Genetics topic: Non-alcoholic fatty liver disease, narrowing the range of covered topics.
    Difference
    0.2%
    Check dated 2025-10-17T02:23:31.000Z thumbnail image
  5. Check
    29 days ago
    Change Detected
    Summary
    Updated regional naming from Rhone-Alpes to Auvergne-Rhône-Alpes and adjusted the Lyon listing to reflect the current region designation.
    Difference
    4%
    Check dated 2025-10-09T23:16:05.000Z thumbnail image
  6. Check
    36 days ago
    Change Detected
    Summary
    Core content updated to include government operating status notice and new version v3.2.0; prior version v3.0.2 removed.
    Difference
    2%
    Check dated 2025-10-02T19:36:12.000Z thumbnail image
  7. Check
    44 days ago
    Change Detected
    Summary
    Removed multiple high-importance terms (Drug Safety, Counterfeit Drugs, Pharmaceutical Preparations, Substandard Drugs) from the page, reducing emphasis on safety/regulatory topics without adding new content.
    Difference
    0.2%
    Check dated 2025-09-25T11:36:48.000Z thumbnail image

Stay in the know with updates to Resmetirom in NASH and Fibrosis Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Resmetirom in NASH and Fibrosis Clinical Trial page.